Autochthonous tumors driven by <i>Rb1</i> loss have an ongoing requirement for the RBP2 histone demethylase
Samuel K. McBrayer(The University of Texas Southwestern Medical Center), William G. Kaelin(Broad Institute), Benjamin A. Olenchock(Regeneron (United States)), Javid J. Moslehi(Cardiovascular Institute of the South), Rebecca Modiste(Dana-Farber Cancer Institute), Julie-Aurore Losman(Brigham and Women's Hospital), Diana D. Shi(Harvard University), Sabina Signoretti(Brigham and Women's Hospital), Roderick T. Bronson(Harvard University), Rebecca B. Jennings(IHS Markit (United States)), Matthew G. Oser(Harvard University), Jesse Novak(Brigham and Women's Hospital), Alissa K. Robbins(Dana-Farber Cancer Institute), Januka Khanal(Brigham and Women's Hospital), Dennis M. Bonal(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan)), Quang-Dé Nguyen(Dana-Farber Cancer Institute), Gabriel J. DiNatale(Harvard University)
Cited by 16
Related Papers
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O <sub>2</sub> Sensing
|Science|2001|4.7k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k